The stock of Cullinan Therapeutics Inc (NASDAQ: CGEM) has decreased by -9.33 when compared to last closing price of 11.04.Despite this, the company has seen a loss of -15.03% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-09 that Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalertinib targets a tiny niche in the large NSCLC market. Management expects to report its Phase 2b results by mid-2025. Similarly, CLN-978 is a first-in-class T-cell engager targeting SLE and RA. It can also potentially be expanded into other B-cell-mediated indications eventually.
Is It Worth Investing in Cullinan Therapeutics Inc (NASDAQ: CGEM) Right Now?
CGEM has 36-month beta value of -0.13. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGEM is 36.83M, and currently, short sellers hold a 26.65% ratio of that float. The average trading volume of CGEM on January 15, 2025 was 527.62K shares.
CGEM’s Market Performance
CGEM’s stock has seen a -15.03% decrease for the week, with a -20.05% drop in the past month and a -38.29% fall in the past quarter. The volatility ratio for the week is 9.01%, and the volatility levels for the past 30 days are at 7.19% for Cullinan Therapeutics Inc The simple moving average for the past 20 days is -14.29% for CGEM’s stock, with a -42.89% simple moving average for the past 200 days.
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with UBS repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to UBS is $30 based on the research report published on October 24, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CGEM reach a price target of $40. The rating they have provided for CGEM stocks is “Buy” according to the report published on May 01st, 2024.
CGEM Trading at -23.39% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.84% of loss for the given period.
Volatility was left at 7.19%, however, over the last 30 days, the volatility rate increased by 9.01%, as shares sank -17.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.29% lower at present.
During the last 5 trading sessions, CGEM fell by -15.03%, which changed the moving average for the period of 200-days by -43.54% in comparison to the 20-day moving average, which settled at $11.68. In addition, Cullinan Therapeutics Inc saw -17.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Michaelson Jennifer, who sale 4,000 shares at the price of $12.51 back on Jan 06 ’25. After this action, Michaelson Jennifer now owns 95,760 shares of Cullinan Therapeutics Inc, valued at $50,040 using the latest closing price.
JENNIFER MICHAELSON, the Officer of Cullinan Therapeutics Inc, proposed sale 8,000 shares at $12.68 during a trade that took place back on Jan 06 ’25, which means that JENNIFER MICHAELSON is holding shares at $101,440 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.3. Equity return is now at value -26.18, with -25.01 for asset returns.
Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -51.84.
Currently, EBITDA for the company is -190.34 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.46.
Conclusion
To put it simply, Cullinan Therapeutics Inc (CGEM) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
